ATC code J07

Last updated

ATCcodeJ07Vaccines is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup J07 is part of the anatomical group J Antiinfectives for systemic use. [4]

Contents

National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

J07A Bacterial vaccines

J07AC Anthrax vaccines

J07AC01 Anthrax antigen

J07AD Brucellosis vaccines

J07AD01 Brucella antigen

J07AE Cholera vaccines

J07AE01 Cholera, inactivated, whole cell
J07AE02 Cholera, live attenuated
J07AE51 Cholera, combinations with typhoid vaccine, inactivated, whole cell

J07AF Diphtheria vaccines

J07AF01 Diphtheria toxoid

J07AG Haemophilus influenzae B vaccines

J07AG01 Hemophilus influenzae B, purified antigen conjugated
J07AG51 Hemophilus influenzae B, combinations with toxoids
J07AG52 Hemophilus influenzae B, combinations with pertussis and toxoids
J07AG53 Hemophilus influenzae B, combinations with meningococcus C, conjugated
J07AG54 Haemophilus influenza B, combinations with meningococcus C, Y, conjugated

J07AH Meningococcal vaccines

J07AH01 Meningococcus A, purified polysaccharides antigen
J07AH02 Other meningococcal monovalent purified polysaccharides antigen
J07AH03 Meningococcus A, C, bivalent purified polysaccharides antigen
J07AH04 Meningococcus A, C, Y, W-135, tetravalent purified polysaccharides antigen
J07AH05 Other meningococcal polyvalent purified polysaccharides antigen
J07AH06 Meningococcus B, outer membrane vesicle vaccine
J07AH07 Meningococcus C, purified polysaccharides antigen conjugated
J07AH08 Meningococcus A, C, Y, W-135, tetravalent purified polysaccharides antigen conjugated
J07AH09 Meningococcus B, multicomponent vaccine
J07AH10 Meningococcus A, purified polysaccharides antigen conjugated

J07AJ Pertussis vaccines

J07AJ01 Pertussis, inactivated, whole cell
J07AJ02 Pertussis, purified antigen
J07AJ51 Pertussis, inactivated, whole cell, combinations with toxoids
J07AJ52 Pertussis, purified antigen, combinations with toxoids

J07AK Plague vaccines

J07AK01 Plague, inactivated, whole cell

J07AL Pneumococcal vaccines

J07AL01 Pneumococcus, purified polysaccharides antigen
J07AL02 Pneumococcus, purified polysaccharides antigen conjugated
J07AL52 Pneumococcus purified polysaccharides antigen and Haemophilus influenzae, conjugated

J07AM Tetanus vaccines

J07AM01 Tetanus toxoid
J07AM51 Tetanus toxoid, combinations with diphtheria toxoid
J07AM52 Tetanus toxoid, combinations with tetanus immunoglobulin

J07AN Tuberculosis vaccines

J07AN01 Tuberculosis, live attenuated

J07AP Typhoid vaccines

J07AP01 Typhoid, oral, live attenuated
J07AP02 Typhoid, inactivated, whole cell
J07AP03 Typhoid, purified polysaccharide antigen
J07AP10 Typhoid, combinations with paratyphi types

J07AR Typhus (exanthematicus) vaccines

J07AR01 Typhus exanthematicus, inactivated, whole cell

J07AX Other bacterial vaccines

J07AX01 Leptospira vaccines

J07B Viral vaccines

J07BA Encephalitis vaccines

J07BA01 Encephalitis, tick-borne, inactivated, whole virus
J07BA02 Encephalitis, Japanese, inactivated, whole virus
J07BA03 Encephalitis, Japanese, live attenuated

J07BB Influenza vaccines

J07BB01 Influenza inactivated, whole virus
J07BB02 Influenza, purified antigen
J07BB03 Influenza, live attenuated
J07BB04 Influenza, virus like particles

J07BC Hepatitis vaccines

J07BC01 Hepatitis B, purified antigen
J07BC02 Hepatitis A, inactivated, whole virus
J07BC20 Combinations

J07BD Measles vaccines

J07BD01 Measles, live attenuated
J07BD51 Measles, combinations with mumps, live attenuated
J07BD52 Measles, combinations with mumps and rubella, live attenuated
J07BD53 Measles, combinations with rubella, live attenuated
J07BD54 Measles, combinations with mumps, rubella and varicella, live attenuated

J07BE Mumps vaccines

J07BE01 Mumps, live attenuated

J07BF Poliomyelitis vaccines

J07BF01 Poliomyelitis oral, monovalent live attenuated
J07BF02 Poliomyelitis oral, trivalent, live attenuated
J07BF03 Poliomyelitis, trivalent, inactivated, whole virus
J07BF04 Poliomyelitis oral, bivalent, live attenuated

J07BG Rabies vaccines

J07BG01 Rabies, inactivated, whole virus

J07BH Rotavirus diarrhea vaccines

J07BH01 Rotavirus, live attenuated
J07BH02 Rotavirus, pentavalent, live, reassorted

J07BJ Rubella vaccines

J07BJ01 Rubella, live attenuated
J07BJ51 Rubella, combinations with mumps, live attenuated

J07BK Varicella zoster vaccines

J07BK01 Varicella, live attenuated
J07BK02 Zoster, live attenuated
J07BK03 Zoster, purified antigen

J07BL Yellow fever vaccines

J07BL01 Yellow fever, live attenuated

J07BM Papillomavirus vaccines

J07BM01 Papillomavirus (human types 6, 11, 16, 18)
J07BM02 Papillomavirus (human types 16, 18)
J07BM03 Papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58)

J07BN Covid-19 vaccines

J07BN01 Covid-19, RNA-based vaccine
J07BN02 Covid-19, viral vector, non-replicating
J07BN03 Covid-19, inactivated virus
J07BN04 Covid-19, protein subunit
J07BN05 Covid-19, virus-like particles

J07BX Other viral vaccines

J07BX01 smallpox and monkeypox vaccines
J07BX02 Ebola vaccines
J07BX04 Dengue virus vaccines
J07BX05 Respiratory syncytial virus vaccines
J07BX06 Enterovirus 71 vaccines

J07C Bacterial and viral vaccines

J07CA Bacterial and viral vaccines, combined

J07CA01 Diphtheria-poliomyelitis-tetanus
J07CA02 Diphtheria-pertussis-poliomyelitis-tetanus
J07CA03 Diphtheria-rubella-tetanus
J07CA04 Hemophilus influenzae B and poliomyelitis
J07CA05 Diphtheria-hepatitis B-pertussis-tetanus
J07CA06 Diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus
J07CA07 Diphtheria-hepatitis B-tetanus
J07CA08 Hemophilus influenzae B and hepatitis B
J07CA09 Diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B
J07CA10 Typhoid-hepatitis A
J07CA11 Diphtheria-Hemophilus influenzae B-pertussis-tetanus-hepatitis B
J07CA12 Diphtheria-pertussis-poliomyelitis-tetanus-hepatitis B
J07CA13 Diphtheria-hemophilus influenzae B-pertussis-tetanus-hepatitis B-meningococcus A + C

J07X Other vaccines

J07XA Parasitic vaccines

J07XA01 Malaria vaccines

See also

Related Research Articles

<span class="mw-page-title-main">Vaccine</span> Pathogen-derived preparation that provides acquired immunity to an infectious disease

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious or malignant disease. The safety and effectiveness of vaccines has been widely studied and verified. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and recognize further and destroy any of the microorganisms associated with that agent that it may encounter in the future.

<span class="mw-page-title-main">DPT vaccine</span> Combination vaccine

The DPT vaccine or DTP vaccine is a class of combination vaccines to protect against three infectious diseases in humans: diphtheria, pertussis, and tetanus (lockjaw). The vaccine components include diphtheria and tetanus toxoids, and either killed whole cells of the bacterium that causes pertussis or pertussis antigens. The term toxoid refers to vaccines which use an inactivated toxin produced by the pathogen which they are targeted against to generate an immune response. In this way, the toxoid vaccine generates an immune response which is targeted against the toxin which is produced by the pathogen and causes disease, rather than a vaccine which is targeted against the pathogen itself. The whole cells or antigens will be depicted as either "DTwP" or "DTaP", where the lower-case "w" indicates whole-cell inactivated pertussis and the lower-case "a" stands for "acellular". In comparison to alternative vaccine types, such as live attenuated vaccines, the DTP vaccine does not contain any live pathogen, but rather uses inactivated toxoid to generate an immune response; therefore, there is not a risk of use in populations that are immune compromised since there is not any known risk of causing the disease itself. As a result, the DTP vaccine is considered a safe vaccine to use in anyone and it generates a much more targeted immune response specific for the pathogen of interest.

<span class="mw-page-title-main">Conjugate vaccine</span> Type of vaccine

A conjugate vaccine is a type of subunit vaccine which combines a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

<span class="mw-page-title-main">Toxoid</span> Weakened form of a toxin, often used for vaccines

A toxoid is an inactivated toxin whose toxicity has been suppressed either by chemical (formalin) or heat treatment, while other properties, typically immunogenicity, are maintained. Toxins are secreted by bacteria, whereas toxoids are altered form of toxins; toxoids are not secreted by bacteria. Thus, when used during vaccination, an immune response is mounted and immunological memory is formed against the molecular markers of the toxoid without resulting in toxin-induced illness. Such a preparation is also known as an anatoxin. There are toxoids for prevention of diphtheria, tetanus and botulism.

<span class="mw-page-title-main">Childhood immunizations in the United States</span>

The schedule for childhood immunizations in the United States is published by the Centers for Disease Control and Prevention (CDC). The vaccination schedule is broken down by age: birth to six years of age, seven to eighteen, and adults nineteen and older. Childhood immunizations are key in preventing diseases with epidemic potential.

<span class="mw-page-title-main">Hib vaccine</span> Haemophilus influenzae type B vaccine

The Haemophilus influenzae type B vaccine, also known as Hib vaccine, is a vaccine used to prevent Haemophilus influenzae type b (Hib) infection. In countries that include it as a routine vaccine, rates of severe Hib infections have decreased more than 90%. It has therefore resulted in a decrease in the rate of meningitis, pneumonia, and epiglottitis.

A vaccine-preventable disease is an infectious disease for which an effective preventive vaccine exists. If a person acquires a vaccine-preventable disease and dies from it, the death is considered a vaccine-preventable death.

<span class="mw-page-title-main">Tetanus vaccine</span> Vaccines used to prevent tetanus

Tetanus vaccine, also known as tetanus toxoid (TT), is a toxoid vaccine used to prevent tetanus. During childhood, five doses are recommended, with a sixth given during adolescence.

Universal Immunisation Programme (UIP) is a vaccination programme launched by the Government of India in 1985. It became a part of Child Survival and Safe Motherhood Programme in 1992 and is currently one of the key areas under the National Health Mission since 2005. The programme now consists of vaccination for 12 diseases- tuberculosis, diphtheria, pertussis, tetanus, poliomyelitis, measles, hepatitis B, rotaviral gastroenteritis, Japanese encephalitis, rubella, pneumonia and Pneumococcal diseases. Hepatitis B and Pneumococcal diseases were added to the UIP in 2007 and 2017 respectively. The cost of all the vaccines are borne entirely by the Government of India and is funded through taxes with a budget of 7,234 crore (US$870 million) in 2022 and the program covers all residents of India, including foreign residents.

<span class="mw-page-title-main">Rachel Schneerson</span> Israeli-American vaccinologist

Rachel Schneerson is a former senior investigator in the Laboratory in Developmental and Molecular Immunity and head of the Section on Bacterial Disease Pathogens and Immunity within the Laboratory at the Eunice Kennedy Shriver National Institute of Child Health and Human Development within the National Institutes of Health. She is best known for her development of the vaccine against bacterial meningitis with her colleague John B. Robbins.

The Norwegian Institute of Public Health is responsible for maintaining and revising the list of notifiable diseases in Norway and participates in the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization's surveillance of infectious diseases. The notifiable diseases are classified into Group A, Group B and Group C diseases, depending on the procedure for reporting the disease.

DTaP-IPV/Hib vaccine is a 5-in-1 combination vaccine that protects against diphtheria, tetanus, whooping cough, polio, and Haemophilus influenzae type B.

DTaP-IPV-HepB vaccine is a combination vaccine whose generic name is diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated polio vaccine or DTaP-IPV-Hep B. It protects against the infectious diseases diphtheria, tetanus, pertussis, poliomyelitis, and hepatitis B.

<span class="mw-page-title-main">Hexavalent vaccine</span> Single vaccine protecting against six individual diseases

A hexavalent vaccine, or 6-in-1 vaccine, is a combination vaccine with six individual vaccines conjugated into one, intended to protect people from multiple diseases. The term usually refers to the children's vaccine that protects against diphtheria, tetanus, pertussis, poliomyelitis, haemophilus B, and hepatitis B, which is used in more than 90 countries around the world including in Europe, Canada, Australia, Jordan, and New Zealand.

A notifiable disease is one which the law requires to be reported to government authorities.

<span class="mw-page-title-main">National Immunisation Program Schedule</span>

The Australian National Immunisation Program Schedule sets out the immunisations Australians are given at different stages in their life. The program aims to reduce the number of preventable disease cases in Australia by increasing national immunisation coverage. The program starts for an Australian when they are born. Vaccinations are given at birth, then again when the baby is 2 months, 4 months, 6 months, 12 months and 18 months. The immunisation schedule continues when the child is 4 years old, and then into adolescent years. The program is not compulsory and parents have the choice if they want their child vaccinated.

<span class="mw-page-title-main">Vaccine ingredients</span> Ingredients used in a vaccine dose

A vaccine dose contains many ingredients very little of which is the active ingredient, the immunogen. A single dose may have merely nanograms of virus particles, or micrograms of bacterial polysaccharides. A vaccine injection, oral drops or nasal spray is mostly water. Other ingredients are added to boost the immune response, to ensure safety or help with storage, and a tiny amount of material is left-over from the manufacturing process. Very rarely, these materials can cause an allergic reaction in people who are very sensitive to them.

References

  1. "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health . Retrieved 1 February 2020.
  2. World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
  3. "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
  4. "ATC/DDD Index 2022: code J07". WHO Collaborating Centre for Drug Statistics Methodology.